Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies

Table 1

mAb combined with nanoparticles for a therapeutic application.

Particle type	mAb	Secondary Payload	Mechanism	Disease	Literature studies
Mesoporous silica	-CTLA 4, 8	—	mAb effector functions	Melanoma	Lei et al., 2010 [31]
	-Mesothelin	DOX	Drug cytotoxicity	Mesothelioma	Macura et al., 2013 [32]
	-EGFR	Pyrrolidine-2	Drug cytotoxicity	Lung cancer	Sundarraj et al., 2014 [33]
	TRC105	DOX/^64Cu	Drug cytotoxicity	Tumors	Chen et al., 2013 and 2014 [34, 35]
Porous Silicon	Bevacizumab	—	Predicted for mAb effector functions	Cancer	Andrew et al., 2010 [36]
	-MLR2	Camptothecin	Drug cytotoxicity	Neuroblastoma	Secret et al., 2013 [37]
	mAb528; (-CCL24)	Camptothecin	Drug cytotoxicity	Glioblastoma	Secret et al., 2013 [37]
	Rituximab; (-CD20)	Camptothecin	Drug cytotoxicity	B Lymphoma	Secret et al., 2013 [37]
	FGK45; (-CD20)	—	Activate B cells	Autoimmune disease	Gu et al., 2012 [38]
Gold	Tocilizumab; (-IL-6)	—	mAb effector functions	Rheumatoid arthritis	Lee et al., 2014 [39]
	Rituximab; (-CD20)	—	Photothermal ablation and mAb effector functions	Lymphoma	Bisker et al., 2012 [40]
Gold Nanorods	-ICAM-1	^125I	Predicted for mAb effector functions	Rheumatoid arthritis	Shao et al., 2011 [41]
	-EGFR	—	Infrared light induced cytotoxicity	Bladder cancer	Cho et al., 2014 [42]
MFNP	α-HER2	—	Photothermal ablation	Breast cancer	Shen et al., 2014 [43]
Nanographene	TRC105; (-CD105)	—	Predicted for photothermal ablation and mAb effector functions	Breast cancer	Hong et al., 2012 [44]
SPION	-neu receptor	—	Predicted for mAb effector functions	Breast cancer	Kievit et al., 2012 [45]

MFNP = multifunctional nanoparticles. SPION = superparamagnetic iron oxide nanoparticle. ICAM1 = intercellular adhesion molecule 1. DOX = doxorubicin.